NTRA

Natera Inc

Jan 28 • 01:25PM ET

237.84

-2.50 -1.04 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH TXG EXAS QGEN FLGT TWST MYGN CDNA BNGO

| Held by: VTI VB VBK VXF IBB IWP IWF IWR XBI ARKK

Index	-	P/E	-	EPS (ttm)	-2.28	Insider Own	4.90%	Shs Outstand	137.53M	Perf Week	-2.03%
Market Cap	32.90B	Forward P/E	-	EPS next Y	-1.91	Insider Trans	-10.32%	Shs Float	131.55M	Perf Month	1.75%
Enterprise Value	32.05B	PEG	-	EPS next Q	-0.51	Inst Own	93.87%	Short Float	2.63%	Perf Quarter	23.73%
Income	-309.19M	P/S	15.54	EPS this Y	-56.68%	Inst Trans	-0.28%	Short Ratio	2.56	Perf Half Y	75.09%
Sales	2.12B	P/B	26.12	EPS next Y	20.39%	ROA	-18.12%	Short Interest	3.46M	Perf YTD	3.82%
Book/sh	9.10	P/C	31.56	EPS next 5Y	46.31%	ROE	-29.02%	52W High	256.36 -7.22%	Perf Year	43.92%
Cash/sh	7.54	P/FCF	310.19	EPS past 3/5Y	33.57% 3.18%	ROIC	-22.79%	52W Low	125.38 89.70%	Perf 3Y	450.17%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.47% 41.20%	Gross Margin	63.66%	Volatility	3.26% 3.64%	Perf 5Y	98.22%
Dividend TTM	-	EV/Sales	15.14	EPS Y/Y TTM	-28.77%	Oper. Margin	-16.62%	ATR (14)	8.03	Perf 10Y	2615.07%
Dividend Ex-Date	-	Quick Ratio	3.13	Sales Y/Y TTM	38.17%	Profit Margin	-14.61%	RSI (14)	51.58	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	3.27	EPS Q/Q	-150.04%	SMA20	-0.24%	Beta	1.63	Target Price	258.90
Payout	-	Debt/Eq	0.16	Sales Q/Q	34.66%	SMA50	1.70%	Rel Volume	0.38	Prev Close	240.34
Employees	4434	LT Debt/Eq	0.08	Earnings	Nov 06 AMC	SMA200	30.96%	Avg Volume	1.35M	Price	237.84
IPO	Jul 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-65.93% 15.33%	Trades		Volume	316,449	Change	-1.04%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Initiated	Citigroup	Buy	$300
Dec-02-25	Resumed	Morgan Stanley	Overweight	$265
Oct-27-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$172
Sep-22-25	Resumed	Wells Fargo	Equal Weight	$175
Mar-13-25	Initiated	RBC Capital Mkts	Outperform	$251
Jan-23-25	Initiated	Barclays	Overweight	$200
Jun-03-24	Resumed	Jefferies	Buy	$142
Apr-08-24	Resumed	Craig Hallum	Buy	$117
Feb-20-24	Downgrade	Raymond James	Strong Buy → Outperform	$68 → $85
Dec-29-23	Reiterated	BTIG Research	Buy	$75 → $85
Dec-14-23	Initiated	Guggenheim	Buy	$70
Dec-13-23	Initiated	Wolfe Research	Outperform	$70
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48
Jul-05-23	Resumed	JP Morgan	Overweight	$85
May-05-23	Initiated	UBS	Buy	$76
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Aug-25-22	Initiated	Credit Suisse	Outperform	$70
Apr-25-22	Initiated	Stephens	Overweight	$54
Mar-08-22	Initiated	Goldman	Buy	$90

Show Previous Ratings

Jan-26-26 06:00AM	Prospera Featured in Landmark Interventional Study Advancing Lung Transplant Care (Business Wire)
Jan-25-26 11:38PM	2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds (StockStory)
Jan-23-26 10:53AM	Lack of Natera (NTRA) Exposure Weighs on Mid-Cap Fund Performance (Insider Monkey)
Jan-21-26 06:00AM	Natera Publishes Clinical Validation of Latitude Tissue-Free MRD Test in Colorectal Cancer (Business Wire)
Jan-20-26 06:00AM	Natera's Fetal Focus Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting (Business Wire)
10:45AM	Loading…
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
08:00AM	Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling (Business Wire)
Jan-12-26 10:00AM	Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA (Business Wire)
Jan-11-26 10:48PM	Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera Growth (Business Wire)
Jan-08-26 08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks) -5.83%
Jan-07-26 02:11PM	Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera (CNBC TV)
09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
08:04AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonalds, Moderna, and More (24/7 Wall St.)
08:00AM	Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer (Business Wire)
Jan-05-26 07:25PM	Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI (Business Wire)
07:00AM	Loading…
07:00AM	Natera Launches 21-Gene Fetal Focus Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP Technology (Business Wire)
Dec-31-25 11:56AM	Natera (NTRA) Announces Publication of Findings from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study (Insider Monkey)
Dec-30-25 02:16PM	Medical Stock Hovers Near Buy Point After 46% Gain (Investor's Business Daily)
Dec-26-25 03:40PM	Medical Stocks On The Move In Top Growth List As Health Sector Performance Brightens (Investor's Business Daily)
Dec-23-25 11:03PM	3 Reasons We're Fans of Natera (NTRA) (StockStory)
Dec-22-25 10:19PM	J.P. Morgan Lifts Natera, Inc. (NTRA) Target on Signatera Momentum (Insider Monkey)
08:00AM	Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-25 08:00AM	Natera Announces Publication of Signatera Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer (Business Wire)
Dec-12-25 08:00AM	Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer (Business Wire)
Dec-11-25 10:11AM	Crypto Market 2026 Predictions: Which Coins Will 10x and Which Will Crash? (24/7 Wall St.)
10:11AM	Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks (24/7 Wall St.)
Dec-10-25 07:57PM	Phase III PALLAS Study Shows Signatera MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer (Business Wire)
06:15AM	Natera acquires Foresight Diagnostics for up to $450M (MedTech Dive)
Dec-09-25 08:00AM	Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting (Business Wire)
Dec-08-25 04:46AM	Natera purchases Foresight Diagnostics (Medical Device Network)
07:00AM	Loading…
Dec-05-25 07:00AM	Natera Acquires Foresight Diagnostics (Business Wire)
Dec-03-25 08:00AM	New Signatera Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting (Business Wire)
Dec-02-25 08:00AM	Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera at the San Antonio Breast Cancer Symposium (Business Wire)
Nov-30-25 03:14AM	30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks (Motley Fool)
Nov-24-25 07:00PM	Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know (StockStory)
12:38PM	This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks Hes Buying Now. (24/7 Wall St.)
Nov-21-25 06:55PM	Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know (StockStory)
Nov-20-25 01:25PM	Cathie Wood Targets New Tech Winners, Dumps AMD in Major Shuffle (GuruFocus.com)
Nov-19-25 10:40PM	Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3 (StockStory)
08:00AM	Employees Volunteer Over 1,500 Hours During Natera's Annual Volunteer Month (Business Wire)
Nov-18-25 04:45AM	TD Cowen Lifts Natera (NTRA) Target to $240, Reiterates Buy Rating (Insider Monkey)
Nov-14-25 03:05PM	Stanley Druckenmiller's Strategic Moves: Exiting Philip Morris International Inc with a -3. ... (GuruFocus.com)
07:58AM	Does Natera (NTRA) Have a Long Runway For Growth? (Insider Monkey)
Nov-12-25 08:00AM	Natera Integrates with Flatiron Health's OncoEMR Platform (Business Wire)
Nov-11-25 11:39PM	1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds (StockStory)
Nov-07-25 09:27AM	NTRA Q3 Deep Dive: Oncology Momentum and New Product Expansion Drive Guidance Increase (StockStory)
12:03AM	Natera Inc (NTRA) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions (GuruFocus.com)
Nov-06-25 07:30PM	Here's What Key Metrics Tell Us About Natera (NTRA) Q3 Earnings (Zacks)
05:50PM	Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:02PM	Natera (NASDAQ:NTRA) Delivers Impressive Q3 (StockStory)
04:46PM	Natera: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-04-25 10:19PM	Natera (NTRA) Reports Earnings Tomorrow: What To Expect (StockStory)
Oct-31-25 07:00AM	Natera Announces Expansion to 20 Genes for its Fetal Focus Single-Gene NIPT (Business Wire)
Oct-30-25 07:00AM	Natera to Report its Third Quarter Results on November 6, 2025 (Business Wire)
Oct-28-25 07:00AM	Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity (Business Wire)
Oct-27-25 06:20AM	Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-20-25 11:31PM	Reflecting On Immuno-Oncology Stocks' Q2 Earnings: Natera (NASDAQ:NTRA) (StockStory)
01:35PM	Why Are Natera (NTRA) Shares Soaring Today (StockStory)
01:05AM	Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients (Business Wire)
Oct-16-25 08:00AM	Natera Named to Fast Company's Next Big Things in Tech List (Business Wire)
Oct-13-25 09:28AM	Natera Signatera Validation Study Published in JCO PO Shows Superior Prognostic Value in Testicular Cancer (Insider Monkey)
08:00AM	Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings (Business Wire)
Oct-12-25 06:10PM	Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium (Business Wire)
Oct-06-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Sep-30-25 08:00AM	Natera Announces Publication of Signatera Validation Study in Testicular Cancer (Business Wire)
Sep-29-25 08:00AM	Signatera Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows (Business Wire)
12:36AM	2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds (StockStory)
Sep-24-25 04:05PM	Why Natera (NTRA) Stock Is Down Today (StockStory) -5.16%
Sep-23-25 01:13PM	Biotech Stocks Rally. 3 Favorite Plays From the Charts. (Barrons.com)
Sep-22-25 09:35AM	Humana initiated, Paycom upgraded: Wall Street's top analyst calls (The Fly)
Sep-12-25 04:01PM	Why Natera (NTRA) Stock Is Trading Lower Today (StockStory)
Sep-10-25 03:11PM	Why Natera (NTRA) Shares Are Falling Today (StockStory)
12:02AM	3 Reasons We're Fans of Natera (NTRA) (StockStory)
Sep-02-25 01:04AM	Natera (NTRA) Provides an Update on its Intellectual Property Litigation With NeoGenomics (Insider Monkey)
Aug-29-25 05:05PM	Health Care Roundup: Market Talk (The Wall Street Journal)
01:46PM	Why Natera (NTRA) Stock Is Down Today (StockStory)
01:04PM	NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims (Benzinga)
08:18AM	Natera Provides Update on Patent Litigation with NeoGenomics (Business Wire)
04:46AM	Nateras Signatera test to be used in Phase III bladder cancer trial (Medical Device Network)
Aug-28-25 03:56PM	Why Natera (NTRA) Stock Is Up Today (StockStory)
08:00AM	Signatera Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer (Business Wire)
Aug-25-25 12:52PM	Natera Shares Rise on the Launch of AI Platform for Precision Oncology (Zacks)
08:00AM	Natera to Present Signatera Data at the IASLC World Conference on Lung Cancer (Business Wire)
Aug-22-25 06:04AM	Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine (Business Wire)
05:00AM	Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation (Business Wire)
12:40AM	1 Healthcare Stock to Own for Decades and 2 We Find Risky (StockStory)
Aug-18-25 12:33PM	Natera pursues ctDNA assay approval after Phase III victory (Clinical Trials Arena)
06:00AM	IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera Strongly Predicting Adjuvant Immunotherapy Benefit (Business Wire)
Aug-15-25 07:15PM	Stanley Druckenmiller's Strategic Moves: Significant Reduction in Coupang Inc. by 3.73% (GuruFocus.com)
Aug-14-25 06:06PM	Liberty All-Star® Growth Fund, Inc. July 2025 Monthly Update (Business Wire)
01:41AM	5 Revealing Analyst Questions From Natera's Q2 Earnings Call (StockStory)
Aug-13-25 07:30AM	1 Strong Buy Stock Analysts Think Will Soar 62% (Barchart)
Aug-12-25 03:27AM	NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures (StockStory)
Aug-08-25 12:21PM	Why Are Natera (NTRA) Shares Soaring Today (StockStory) +7.70%
06:21AM	Natera introduces prenatal test for detecting inherited conditions (Medical Device Network)
05:33AM	Natera (NASDAQ:NTRA) Delivers Strong Q2 Numbers, Stock Jumps 12.6% (StockStory)
Aug-07-25 07:00PM	Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics (Zacks)
06:15PM	Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:12PM	Natera: Q2 Earnings Snapshot (Associated Press Finance)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sheena Jonathan	CO-FOUNDER	Jan 23 '26	Sale	243.94	1,500	365,914	21,782	Jan 27 08:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 20 '26	Sale	234.74	71,932	16,885,203	217,354	Jan 22 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 21 '26	Sale	235.00	1,590	373,650	219,150	Jan 22 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 21 '26	Sale	242.54	37,175	9,016,585	64,123	Jan 22 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 20 '26	Sale	234.74	23,948	5,621,515	99,776	Jan 22 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 21 '26	Sale	234.46	3,163	741,612	264,078	Jan 22 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jan 20 '26	Sale	234.74	2,981	699,755	267,050	Jan 22 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 20 '26	Sale	234.74	19,234	4,514,958	226,615	Jan 22 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 21 '26	Sale	235.00	438	102,930	227,033	Jan 22 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 20 '26	Sale	234.74	23,205	5,447,105	144,992	Jan 22 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 21 '26	Sale	235.00	293	68,855	144,699	Jan 22 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 20 '26	Sale	234.74	17,806	4,179,752	177,591	Jan 22 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 21 '26	Sale	235.00	339	79,665	177,252	Jan 22 09:05 PM
MICHAEL BROPHY	Officer	Jan 21 '26	Proposed Sale	234.85	36,573	8,589,169		Jan 21 04:54 PM
Sheena Jonathan	CO-FOUNDER	Jan 05 '26	Option Exercise	9.59	39,615	379,908	262,581	Jan 06 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 02 '26	Sale	228.95	2,951	675,621	123,499	Jan 06 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 02 '26	Sale	229.08	3,848	881,482	136,568	Jan 06 09:05 PM
SOLOMON MOSHKEVICH	Officer	Jan 02 '26	Proposed Sale	228.95	2,951	675,621		Jan 02 04:13 PM
STEVEN L CHAPMAN	Officer	Jan 02 '26	Proposed Sale	229.08	3,848	881,482		Jan 02 04:13 PM
Sheena Jonathan	CO-FOUNDER	Dec 19 '25	Sale	225.94	1,500	338,914	22,532	Dec 22 08:05 PM
Sheena Jonathan	Director	Dec 19 '25	Proposed Sale	220.00	4,500	990,000		Dec 19 10:03 AM
Sheena Jonathan	CO-FOUNDER	Dec 17 '25	Sale	227.01	3,070	696,912	222,966	Dec 17 08:35 PM
Sheena Jonathan	Director	Dec 17 '25	Proposed Sale	228.00	9,210	2,099,880		Dec 17 11:44 AM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 12 '25	Option Exercise	9.59	22,376	214,586	126,565	Dec 16 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 12 '25	Sale	230.76	4,692	1,082,714	113,065	Dec 16 09:05 PM
ROSENMAN HERM	Director	Dec 12 '25	Sale	227.42	48,419	11,011,477	20,342	Dec 16 09:05 PM
SOLOMON MOSHKEVICH	Officer	Dec 12 '25	Proposed Sale	230.76	4,692	1,082,714		Dec 12 05:17 PM
Herm Rosenman Trust	Board member	Dec 12 '25	Proposed Sale	233.13	48,419	11,287,921		Dec 12 10:07 AM
Sheena Jonathan	CO-FOUNDER	Dec 09 '25	Option Exercise	9.29	4,436	41,210	227,096	Dec 11 08:35 PM
Chapman Rowan E	Director	Dec 05 '25	Option Exercise	32.15	4,000	128,600	10,143	Dec 09 08:35 PM
Chapman Rowan E	Director	Dec 05 '25	Sale	243.10	4,366	1,061,389	5,777	Dec 09 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Dec 04 '25	Option Exercise	19.68	6,902	135,831	208,601	Dec 08 09:55 PM
ROWAN EMMA CHAPMAN	Director	Dec 05 '25	Proposed Sale	243.10	4,366	1,061,391		Dec 05 07:25 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 01 '25	Sale	238.15	3,000	714,459	109,061	Dec 03 08:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Dec 01 '25	Sale	238.07	4,400	1,047,502	140,416	Dec 03 08:35 PM
STEVEN L CHAPMAN	Officer	Dec 01 '25	Proposed Sale	238.07	4,400	1,047,501		Dec 01 04:10 PM
SOLOMON MOSHKEVICH	Officer	Dec 01 '25	Proposed Sale	238.15	3,000	714,459		Dec 01 04:08 PM
BOTHA ROELOF	Director	Nov 24 '25	Sale	236.12	75,000	17,708,936	1,154,198	Nov 26 05:00 PM
BV369 TRUST	Affiliate	Nov 24 '25	Proposed Sale	236.12	75,000	17,709,000		Nov 24 04:50 PM
Sheena Jonathan	CO-FOUNDER	Nov 20 '25	Sale	225.08	10,000	2,250,816	222,660	Nov 21 08:05 PM
Sheena Jonathan	CO-FOUNDER	Nov 21 '25	Sale	230.01	4,000	920,030	23,282	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 20 '25	Option Exercise	41.17	7,668	315,689	26,027	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 19 '25	Option Exercise	40.93	5,112	209,234	23,471	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 20 '25	Sale	223.08	7,668	1,710,600	18,359	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 19 '25	Sale	215.00	5,112	1,099,088	18,359	Nov 21 08:05 PM
ROY BAYNES	Director	Nov 20 '25	Proposed Sale	223.08	7,668	1,710,600		Nov 20 04:03 PM
Sheena Jonathan	Director	Nov 20 '25	Proposed Sale	225.02	10,000	2,250,186		Nov 20 11:21 AM
ROY BAYNES	Director	Nov 19 '25	Proposed Sale	215.00	5,112	1,099,088		Nov 19 04:04 PM
Sheena Jonathan	CO-FOUNDER	Nov 07 '25	Sale	192.56	3,070	591,159	232,660	Nov 12 08:35 PM
Sheena Jonathan	CO-FOUNDER	Nov 11 '25	Sale	207.96	1,500	311,934	25,282	Nov 12 08:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 04 '25	Sale	200.51	22,900	4,591,674	2,280,852	Nov 04 09:35 PM
Sheena Jonathan	CO-FOUNDER	Nov 03 '25	Sale	200.07	4,000	800,274	26,032	Nov 04 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Nov 03 '25	Sale	198.60	3,000	595,810	112,061	Nov 04 09:35 PM
Marcus Gail Boxer	Director	Nov 03 '25	Sale	198.71	122	24,243	5,762	Nov 04 09:05 PM
MATTHEW RABINOWITZ	Director	Nov 04 '25	Proposed Sale	198.23	22,900	4,539,467		Nov 04 04:33 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 03 '25	Option Exercise	116.02	155,679	18,062,483	305,519	Nov 03 09:40 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 03 '25	Sale	199.96	160,703	32,133,981	144,816	Nov 03 09:40 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 03 '25	Sale	200.00	17,100	3,420,003	2,303,752	Nov 03 09:35 PM
MATTHEW RABINOWITZ	Director	Nov 03 '25	Proposed Sale	198.93	17,100	3,401,703		Nov 03 04:26 PM
SOLOMON MOSHKEVICH	Officer	Nov 03 '25	Proposed Sale	198.60	3,000	595,810		Nov 03 04:07 PM
STEVEN L CHAPMAN	Officer	Nov 03 '25	Proposed Sale	199.96	160,703	32,133,983		Nov 03 04:03 PM
Gail Marcus	Director	Nov 03 '25	Proposed Sale	198.71	122	24,243		Nov 03 01:24 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 28 '25	Sale	191.46	3,680	704,580	149,840	Oct 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 27 '25	Sale	192.32	2,335	449,077	153,520	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 28 '25	Sale	191.16	2,415	461,648	65,993	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 29 '25	Sale	190.64	1,867	355,925	64,126	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 27 '25	Sale	192.32	781	150,205	68,408	Oct 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Oct 27 '25	Sale	192.32	288	55,389	235,921	Oct 29 09:05 PM
Sheena Jonathan	CO-FOUNDER	Oct 28 '25	Sale	191.46	191	36,569	235,730	Oct 29 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 28 '25	Sale	191.46	1,058	202,567	201,699	Oct 29 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 27 '25	Sale	192.32	935	179,823	202,757	Oct 29 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 28 '25	Sale	191.46	1,198	229,371	115,061	Oct 29 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 27 '25	Sale	192.32	1,008	193,863	116,259	Oct 29 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 28 '25	Sale	191.46	928	177,677	150,699	Oct 29 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 27 '25	Sale	192.32	781	150,205	151,627	Oct 29 09:05 PM
MICHAEL BROPHY	Officer	Oct 29 '25	Proposed Sale	189.57	1,867	353,927		Oct 29 04:23 PM
MICHAEL BROPHY	Officer	Oct 28 '25	Proposed Sale	192.22	1,178	226,435		Oct 28 04:16 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 22 '25	Sale	186.68	920	171,746	69,189	Oct 24 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 24 '25	Sale	196.77	755	148,561	69,189	Oct 24 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 23 '25	Sale	187.16	495	92,644	69,944	Oct 24 09:35 PM
MICHAEL BROPHY	Officer	Oct 24 '25	Proposed Sale	195.00	755	147,225		Oct 24 04:26 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Oct 20 '25	Sale	190.00	10,000	1,900,000	5,000	Oct 22 09:05 PM
Sheena Jonathan	CO-FOUNDER	Oct 21 '25	Sale	187.95	93	17,479	236,209	Oct 22 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 21 '25	Sale	187.95	464	87,209	203,692	Oct 22 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 21 '25	Sale	187.95	292	54,881	117,267	Oct 22 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 21 '25	Sale	187.95	339	63,715	152,408	Oct 22 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 21 '25	Sale	187.95	1,603	301,284	155,855	Oct 22 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 21 '25	Sale	187.95	602	113,146	70,109	Oct 22 09:05 PM
MICHAEL BROPHY	Officer	Oct 22 '25	Proposed Sale	186.88	920	171,930		Oct 22 04:36 PM
TINKERBELLE II TR U/A DTD 10/2	Officer	Oct 20 '25	Proposed Sale	190.00	10,000	1,900,000		Oct 20 04:17 PM
Sheena Jonathan	CO-FOUNDER	Oct 15 '25	Sale	175.47	3,070	538,681	236,112	Oct 17 09:05 PM
Sheena Jonathan	CO-FOUNDER	Oct 17 '25	Sale	178.91	1,500	268,361	28,032	Oct 17 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 01 '25	Sale	159.99	3,000	479,969	117,559	Oct 01 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Sep 30 '25	Sale	162.05	1,364	221,040	203,300	Oct 01 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 01 '25	Sale	160.00	14,083	2,253,233	154,072	Oct 01 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Sep 30 '25	Sale	162.05	9,109	1,476,139	168,155	Oct 01 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Sep 30 '25	Sale	162.05	2,491	403,674	69,189	Oct 01 09:35 PM
STEVEN L CHAPMAN	Officer	Oct 01 '25	Proposed Sale	160.00	14,083	2,253,233		Oct 01 04:21 PM
SOLOMON MOSHKEVICH	Officer	Oct 01 '25	Proposed Sale	159.99	3,000	479,969		Oct 01 04:13 PM
Sheena Jonathan	CO-FOUNDER	Sep 19 '25	Sale	179.47	11,000	1,974,206	28,782	Sep 22 08:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTRA

Natera Inc

Upgrade your FINVIZ experience